Last reviewed · How we verify
Placebo matching with Sitagliptin
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose.
Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase levels of incretin hormones, which stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo matching with Sitagliptin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging the action of these incretin hormones, sitagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion, thereby lowering blood glucose levels in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning insulin is only stimulated when blood glucose is elevated, reducing hypoglycemia risk.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Cardiovascular Effects of GLP-1 Receptor Activation (PHASE4)
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
- A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM (PHASE1)
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 (PHASE1, PHASE2)
- A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching with Sitagliptin CI brief — competitive landscape report
- Placebo matching with Sitagliptin updates RSS · CI watch RSS
- AstraZeneca portfolio CI